. Abès, &. Dutertre, and . Teillard, «Les anticorps: mieux connaitre pour mieux s'en servir.» Medecine Sciences, pp.1011-1019, 2009.

B. Allard, «Production et caractérisation d'anticorps polyclonaux et monoclonaux ciblant les recepteurs des endothélines en vue d'un immunothérapie des cancers, Thèse de doctorat, p.257, 2012.

. Beck, «Anticorps thérapeutiques et dérivés: une palette de structures pour une pléthore d'indications.» Medecine Sciences, pp.1024-1032, 2009.

. «. Biorad, Ceramic Hydroxyapatite Application guides for process development and scaleup, », Bulletin, vol.6086

&. Bross and . Al, «Apprval summary: Gemtuzumab ozogamycin in relapsed acute myeloid leukemia.» Clin, Cancer Res, vol.7, pp.1490-1496, 2001.

&. Casi and . Neri, Antibody???drug conjugates: Basic concepts, examples and future perspectives, Journal of Controlled Release, vol.161, issue.2, pp.422-428, 2012.
DOI : 10.1016/j.jconrel.2012.01.026

&. Dosio and . Al, Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components, Toxins, vol.3, issue.12, pp.848-883, 2011.
DOI : 10.3390/toxins3070848

&. Ducry and . Stump, Antibody???Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies, Bioconjugate Chemistry, vol.21, issue.1, pp.5-13, 2010.
DOI : 10.1021/bc9002019

F. News, « FDA approves Adcetris to treat two types of lymphoma, 2011.

F. News, 21 06 2010. « FDA: Pfizer Voluntarily Withdraws Cancer Treatment Mylotarg from U.S. Market, 2010.

&. Goldmacher and . Kotvun, Antibody???drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells, Therapeutic Delivery, vol.2, issue.3, pp.397-416, 2011.
DOI : 10.4155/tde.10.98

. Haeuw and . Beck, «Les immunoconjugués, anticorps "armés" pour combattre le cancer.» Medecine Sciences, pp.46-1052, 2009.

&. Jakobsson and . Al, Optimisation and robustness analysis of a hydrophobic interaction chromatography step, Journal of Chromatography A, vol.1099, issue.1-2, pp.157-166, 2005.
DOI : 10.1016/j.chroma.2005.09.009

L. Merie and B. Intelligence, « Antibody-Drug Conjugates 2011 -real breakthrough still to come A Technology, Stakeholder and R&D Pipeline Analysis, » Rapport, 2011.

B. Leblanc, Biochimie des protéines, 2011.

F. Louvet and L. Delplanque, « Les plans d'expériences : une approche pragmatique et illustrée -Design of Experiment : The French Touch, » Experimentique, 2005.

K. Lyer, «Antibody drug conjugates: Trojan horses in the war on cancer.» Journal of pharmacological and toxicological methods, pp.207-212, 2011.

&. Marshak and . Al, «Strategies for protein purification and characterization.» Cold spring harbour laboratory press, 1996.

. «. Millipore, A hands-on guide to ultrafiltration/diafiltration optimization using Pellicon® cassettes. », Application Note, 2008.

G. Milstein, Kohler and C. «Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, pp.495-497, 1975.

&. Mistretta and . Coll, «Production des anticorps monoclonaux.» Revue médicale de Liège, pp.248-252, 2009.

&. Nfor and . Al, High-throughput protein precipitation and hydrophobic interaction chromatography: Salt effects and thermodynamic interrelation, Journal of Chromatography A, vol.1218, issue.49, pp.8958-8973, 1218.
DOI : 10.1016/j.chroma.2011.08.016

A. Oschsenbein, «Anticorps monoclonaux comme substances thérapeutiques.» Med Suisse, pp.140-143, 2008.

J. A. Queiroz, Hydrophobic interaction chromatography of proteins, Journal of Biotechnology, vol.87, issue.2, pp.143-159, 2001.
DOI : 10.1016/S0168-1656(01)00237-1

J. M. Reichert, «Antibody-based therapeutics to watch in 2011.» mAbs (Landes Biosciences), pp.76-99, 2011.

A. Ritter, «Antibody-Drug conjugates: Looking Ahead to an Emerging Class of Biotherapeutic.» PharmTech, pp.42-47, 2012.

P. Robert and . Lyon, «Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues.» Methods in Enzymology, pp.124-138, 2012.

A. S. Rosenberg, «Effects of protein aggregates: an immunologic perspective.» The AAPS journal, pp.501-507, 2006.

G. Ross, «Antibody-based therapeutics in oncolongy.» Expert review of Anticancer Therapy, pp.7-121, 2003.

C. Schneider, K. «Monoclonal antibodies -Regulatory Challenges.» Current Pharmaceutical Biotechnology, pp.431-438, 2008.
URL : https://hal.archives-ouvertes.fr/in2p3-00641056

C. Schroeder, Structure and function of immunoglobulins, Journal of Allergy and Clinical Immunology, vol.125, issue.2, pp.41-52, 2010.
DOI : 10.1016/j.jaci.2009.09.046

P. D. Senter, Potent antibody drug conjugates for cancer therapy, Current Opinion in Chemical Biology, vol.13, issue.3, pp.235-244, 2009.
DOI : 10.1016/j.cbpa.2009.03.023

&. Siberil and . Al, «Therapeutic monoclonal antibodies: a short historical perspective, a lot of engineering, and?some clinical successes.» Transfusion Clinique et biologique, pp.114-122, 2005.

. Sun, Reduction???Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides, Bioconjugate Chemistry, vol.16, issue.5, pp.1282-1290, 2005.
DOI : 10.1021/bc050201y

&. Teicher and . Chari, «Antibody drug conjugate therapeutics : Challenges and potential.» Clin Cancer Res, pp.6383-6397, 2011.
DOI : 10.1158/1078-0432.ccr-11-1417

A. Wakankar, «Analytical methods for physicochemical characterization of antibody drug conjugates.» mAbs (Landes Biosciences), pp.161-172, 2011.

W. Wang and &. Al, «Antibody structure, instability, and formulation.» Journal of pharmaceutical sciences, pp.1-26, 2007.
DOI : 10.1002/jps.20727

. Weiner, &. Surana, and . Wang, Monoclonal antibodies: versatile platforms for cancer immunotherapy, Nature Reviews Immunology, vol.279, issue.5, pp.317-327, 2010.
DOI : 10.1038/nri2744

&. Wu and . Senter, «Arming antibodies: Prospects and challenger for immunoconjugates,.» Nature biotechnology, pp.1137-1146, 2005.
DOI : 10.1038/nbt1141

Y. Lu and &. Al, «Recent advancement in application of hydrophobic interaction chromatography for aggregate removal in industrial purification process.» Current Pharmaceutical biotechnology, pp.247-433, 2009.